A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the ...
Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes: Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase ...
J. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med. Rep. 4, 5 (2012). PubMed PubMed Central Google Scholar Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21, 317–324 (2009). CAS PubMed Google ...
4 5 6大,但其他是光。 7被胶合的一个方形的包裹。 有一本书在它。 另一个是长和狭窄的。 它有一把伞在它。 吉姆的姐妹给了他一大, 8[translate] aRationally Designed Kinase Inhibitors as Drugs for Cancer and Autoimmune Diseases 合理地被设计的激酶抗化剂作为药物为巨蟹星座和自体免疫病[translate]...
1.19Phosphoinositide 3-kinase (PI3K) Inhibitors In hematology, idelalisib and duvelisib are used. For idelalisib, no relationships between exposure and response nor toxicity have been described in the literature (n =59) [162,163]. When administered in combination with other drugs (e.g., rituximab...
I. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand. J. Immunol. 78, 130–139 (2013). CAS PubMed Google Scholar Schaeffer, E. M. et al. Tec family kinases modulate thresholds for thymocyte development and selection. J. Exp. ...
The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their int
Kinase inhibitorsare drugs that generally inhibittyrosine kinase(TK) enzymes, which catalyze the transfer of phosphate groups from adenosine triphosphate (ATP) totyrosine residueson proteins.14This process can be an activating event for proteins involved in signaling, and leads to increasedcellular prolif...
In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology. Because this new class of drugs is extensively used, serious drug–drug interactions are an increasing risk. In this Review, we give a comprehensive overview of known or suspected drug–drug...
Because most kinases play a role in >1 cell type, and because most inhibitors have promiscuous effects, the use of these drugs will affect immune responses at multiple levels. However, depending on the timing, method, and state of cellular development in which cells are exposed to TKIs, speci...